Medication Assisted Treatment for Opioid Use Disorder (MOUD): Breaking the Cycle
Information
Recorded
-
-
Learning Objectives
Participants will be able to:
-
Identify key epidemiology of the Opioid Crisis and describe how such statistics impact the healthcare system.
-
Discuss “Harm Reduction” as a patient outcomes & public health strategy.
-
Describe two risk factors and three clinical features of Opioid Use Disorder (OUD).
-
Describe three reasons for which the treatment of opioid use disorder is important.
-
Identify three or more treatment options for opioid use disorder.
-
Compile a list of two or more appropriate stakeholders for engagement throughout treatment program implementation.
-
Develop next steps for implementing an office-based or hospital-based opioid treatment program.
Educational Goal
The educational goal of this workshop is to increase knowledge about the opioid epidemic and treatment.
Description
This presentation provides an introduction to the current drivers of the U.S. Opioid Crisis and the status of the opioid illicit drug market. We will discuss key epidemiology of the opioid crisis harm reduction as a public health strategy. The three medications that are FDA approved for the treatment of opioid use disorder are discussed in detail to include method of action, pharmacological features of each drug, dosing strategies, adverse effects, and clinical pearls. In addition,we discuss the three drugs from a regulatory standpoint and how to construct a therapeutic strategy based on patient characteristics. Best practices for integration of this care into office-based or hospital-based treatment programs are also covered.
Target Audience
- Counselor
- Marriage & Family Therapist
- Social Worker
- Substance Use Disorder Professionals
Presenters
Dr. Joy P. Alonzo received her BS degree in Pharmacy from the University of Pittsburgh, her Masters of Engineering in Engineering Science from the Pennsylvania State University, and her doctoral degree in Pharmacy from Howard University College of Pharmacy. Dr. Alonzo has extensive clinical experience to include pharmacotherapeutic driven patient care, healthcare disparities evaluation and innovation with a special emphasis on rural health and access to care, health system evaluation and development. Her research interests are improving access to primary and specialty care, especially mental and behavior healthcare via the innovative use of technology. Dr. Alonzo has a special focus on substance use disorder prevention, education and treatment and provides support to Mental and Behavioral health focused facilities, organizations, and initiatives across the state of Texas and the U.S. She is partnered in research projects with the Schools of Nursing, Medicine, and Public Health, as well as Rural Community Health Institute. Dr. Alonzo currently serves as a Clinical Associate Professor at the Rangel School of Pharmacy, and is the Co-Chair of the Texas A&M Opioid Task Force.
Financially Sponsored By
- Aetna Better Health of Louisiana